Genovese Burford & Brothers Wealth & Retirement Plan Management LLC bought a new position in Becton Dickinson and Co (NYSE:BDX) during the 4th quarter, HoldingsChannel.com reports. The firm bought 850 shares of the medical instruments supplier’s stock, valued at approximately $207,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Legacy Advisors LLC raised its holdings in Becton Dickinson and by 7,000.0% in the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares during the period. Amica Retiree Medical Trust raised its holdings in Becton Dickinson and by 325.0% in the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares during the period. Almanack Investment Partners LLC. acquired a new stake in Becton Dickinson and in the fourth quarter worth $109,000. FTB Advisors Inc. raised its holdings in shares of Becton Dickinson and by 114.2% during the fourth quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after acquiring an additional 290 shares during the period. Finally, Advisors Preferred LLC acquired a new stake in shares of Becton Dickinson and during the fourth quarter worth $126,000. Institutional investors own 83.37% of the company’s stock.
In other news, EVP James W. Borzi sold 4,048 shares of Becton Dickinson and stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $224.98, for a total value of $910,719.04. Following the completion of the transaction, the executive vice president now owns 5,334 shares of the company’s stock, valued at approximately $1,200,043.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP John E. Gallagher sold 5,346 shares of Becton Dickinson and stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $226.08, for a total transaction of $1,208,623.68. Following the completion of the transaction, the vice president now directly owns 9,391 shares of the company’s stock, valued at approximately $2,123,117.28. The disclosure for this sale can be found here. In the last ninety days, insiders sold 279,231 shares of company stock valued at $60,895,317. 1.00% of the stock is owned by insiders.
Becton Dickinson and Co (BDX) opened at $225.50 on Tuesday. The firm has a market cap of $60,202.75, a price-to-earnings ratio of 172.14, a P/E/G ratio of 1.64 and a beta of 1.18. Becton Dickinson and Co has a 12-month low of $175.66 and a 12-month high of $248.39. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.54 and a quick ratio of 0.93.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.07. The business had revenue of $3.08 billion during the quarter, compared to the consensus estimate of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.33 earnings per share. equities analysts forecast that Becton Dickinson and Co will post 10.94 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 229.01%.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.